A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Alirocumab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-CHOICE-I
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 According to a Regeneron and Sanofi media release, based on the data from this trial, U.S. FDA approved supplemental Biologics License Application for a once-monthly (every four weeks), 300 mg dose of Praluent (alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol. European Commission (EC) also approved the monthly 300 mg dose of Praluent in November 2016.
    • 16 Nov 2016 Results (n=299) of a pharmacodynamic analysis presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top